- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05138042
Chemotherapy - Induced Peripheral Neuropathy
Effect of Cryotherapy on Paclitaxel-Induced Peripheral Neuropathy of the Hand in Female Breast Cancer Patients: A Prospective Self-Controlled Study
The purpose of this study was to examine the efficacy of cryotherapy with frozen gloves for the prevention of the chemotherapy-induced peripheral neuropathy (CIPN) of the hand.
Frozen glove was provided for dominant hand of breast cancer patients while receiving paclitaxel treat, and as the experimental group. In addition, another hand as a control group. The questionnaire was used before chemotherapy and at the fourth, eighth, twelfth, and sixteenth weeks to understand the effectiveness of frozen gloves.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In this study, the cryotherapy interventions were based on previous studies, with the dominant hand wearing the frozen glove set as the experimental group, and the non-dominant hand that was not wearing a frozen glove as the control group. The Elasto-Gel flexible frozen glove (Southwest Technologies, North Kansas City, MO, USA) used in this study lasted for 20 to 40 minutes and was easy to clean.The cold temperature of the refrigerator was measured in advance to be -20.2°C to -22.8°C. The freezing of the gloves lasted for at least three hours, and the gloves were tested with an infrared temperature-measuring instrument before use.
Its temperature range was -24.3°C to -24.7°C. The patient began to wear gloves 15 minutes before the administration of paclitaxel for one hour, and replaced them with new frozen gloves at the 45th minute. The patient continued to wear the gloves until 15 minutes after the end of the chemotherapy drug administration, for a total of 90 minutes. These intervention procedures were used for each treatment for 12 weeks.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Taichung, Taiwan, 40201
- Chung Shan Medical University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women with breast cancer diagnosis confirmed by a physician and receiving paclitaxel for the first time.
- Above 20 years of age.
Exclusion Criteria:
- Patients with neurological disease histories.
- Patients with histories of the hand-foot syndrome.
- Patients with distant cancer metastases or skin metastases.
- Patients with nail lesions or the absence of fingers.
- Patients with a low tolerance to cold, and edema.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intervention side
Breast cancer patients wore frozen glove on the dominant hand for 90 minutes during their weekly treatment with paclitaxel (80 mg/m2).
Treatment was continued for 12 weeks, with their non-dominant hand as the control side
|
In this study, the cryotherapy interventions were based on previous studies, with the dominant hand wearing the frozen glove set as the experimental group, and the non-dominant hand that was not wearing a frozen glove as the control group. The cold temperature of the refrigerator was measured in advance to be -20.2°C to -22.8°C. The freezing of the gloves lasted for at least three hours, and the gloves were tested with an infrared temperature-measuring instrument before use. Its temperature range was -24.3°C to -24.7°C. The patient began to wear gloves 15 minutes before the administration of paclitaxel for one hour, and replaced them with new frozen gloves at the 45th minute. The patient continued to wear the gloves until 15 minutes after the end of the chemotherapy drug administration, for a total of 90 minutes. |
|
No Intervention: Control side
Breast cancer patients wore frozen glove on the dominant hand for 90 minutes during their weekly treatment with paclitaxel (80 mg/m2).
Treatment was continued for 12 weeks, with their non-dominant hand as the control side
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
peripheral neuropath (hand sensory symptoms and hand motor symptoms) "change" is being assessed.
Time Frame: Questionnaire were filled out five times, before the first chemotherapy session and at the fourth, eighth, twelfth, and sixteenth weeks following the first chemotherapy session.
|
The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chemotherapy-Induced Peripheral Neuropathy 20 (EORTC QLQ-CIPN 20) was used to assess chemotherapy-induced peripheral neuropathy in breast cancer patients. It contains 20 items and includes three scales (sensory scale, motor scale, and autonomic scale) In this study, we focused on the evaluation of the peripheral neurological symptoms of the hand according to the purpose of the research. Therefore, we selected the scope related to the hand in the EORTC QLQ-CIPN20 as an assessment item. It contains four items about sensory symptoms and four items about motor symptoms.Each item is rated on a 4-point Likert-type scale ranging from 1 (not at all) to 4 (very much). The total score is the sum of all item scores. Higher scores reflect more peripheral neuropathic signs and symptoms. |
Questionnaire were filled out five times, before the first chemotherapy session and at the fourth, eighth, twelfth, and sixteenth weeks following the first chemotherapy session.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CS2-19004
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer Female
-
University of Kansas Medical CenterRecruitingBreast Cancer FemaleUnited States
-
Institut fuer FrauengesundheitNovartis Pharmaceuticals; AGO Breast Study Group e.V.RecruitingBreast Cancer | Breast Neoplasms | Advanced Breast Cancer | Breast Neoplasm Female | Breast Cancer Female | HER2-negative Breast Cancer | Hormone Receptor-positive Breast CancerGermany
-
Oncoliq US IncRecruitingBreast Cancer Female | Breast Cancer Detection | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Breast Cancer With Low to Intermediate HER2 Expression | Breast Cancer - Female | Breast Cancer (Early Breast Cancer) | Breast Cancer - Ductal Carcinoma in Situ (DCIS) | Breast Cancer - Infiltrating...Argentina
-
Dalarna County Council, SwedenRecruitingBreast Cancer - FemaleSweden
-
Al-Quds UniversityNot yet recruitingThe Effect of Psychosocial Support on Improving Breast Cancer Patients Response to Medical TreatmentBreast Cancer - FemalePalestinian Territories
-
Izmir Biomedicine and Genome CenterDokuz Eylul University; Antalya Training and Research Hospital; Akdeniz University...Enrolling by invitationFemale Breast Cancer PatientsTurkey (Türkiye)
-
University of Central FloridaFlorida Department of HealthRecruitingBreast Cancer | Breast Cancer Female | Breast Cancer Diagnosis | Breast Cancer Survivors | Breast Cancer Detection | Breast Cancer AwarenessUnited States
-
Dana-Farber Cancer InstituteBreast Cancer Research FoundationNot yet recruitingBreast Cancer | Breast Carcinoma | ER Positive Breast Cancer | Breast Cancer - Female | PR-Positive Breast CancerUnited States
-
Carebot s.r.o.CompletedBreast Neoplasms | Breast Cancer Screening | Breast Cancer Detection | Breast Cancer - FemaleCzechia, Slovakia
-
Ahon Pharmaceutical Co., Ltd.RecruitingAdvanced Breast Cancer | Female Breast CancerChina
Clinical Trials on Cryotherapy (frozen glove)
-
Institut Paoli-CalmettesCompletedBreast Neoplasms | Prostate Cancer | Nail DiseasesFrance
-
Peking UniversityCSPC Ouyi Pharmaceutical Co., Ltd.Recruiting
-
Columbia UniversityCompletedCIPN - Chemotherapy-Induced Peripheral NeuropathyUnited States
-
Princess Alexandra Hospital, Brisbane, AustraliaCompleted
-
Chulalongkorn UniversityUnknownParkinson's DiseaseThailand
-
Weill Medical College of Cornell UniversityParker Hannifin CorporationTerminated
-
Fudan UniversityRecruitingLocally Advanced or Metastatic Breast CancerChina
-
Christian CiprianiRecruiting
-
Stanford UniversityNot yet recruitingParkinson DiseaseUnited States
-
Carilion ClinicEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedBrachial Plexus InjuryUnited States